Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: Results of the CLAMORS Study

Bobes, Julio; Arango, Celso; Aranda, Pedro J.; Carmena, Rafael; García-García, Margarida; Rejas, Javier

doi:10.1016/j.schres.2006.09.025

Cited by 172 publications

(131 citation statements)

References 57 publications

Supporting

Mentioning

105

Contrasting

Unclassified

Order By: Relevance

“…Several studies have shown high prevalence rates of MetS in patients with schizophrenia (Basu et al, 2004;Bobes et al, 2007;Cohn et al, 2004;Correll et al, 2006;De Hert et al, 2006a;Heiskanen et al, 2003;Holt et al, 2004;McEvoy et al, 2005;Meyer et al, 2005;Rejas et al, 2008;Sicras-Mainar et al, 2008;Srisurapanont et al, 2007;Thakore, 2005). Rates of MetS in people with schizophrenia are at least double compared to an age matched population sample (De Hert et al, 2006b).…”

Section: Introductionmentioning

confidence: 99%

Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review

Hert

Schreurs

Sweers

et al. 2008

Schizophrenia Research

219

118

View full text Add to dashboard Cite

The presence of the metabolic syndrome (MetS) is an important risk factor for cardiovascular disease and diabetes. There are limited data on the prevalence of MetS in patients with schizophrenia at the onset of the disorder and specifically no data on patients treated in the era when only first-generation antipsychotics were available.Methods: Data from a historic cohort of consecutively admitted first-episode patients with schizophrenia treated with first-generation antipsychotics (FGAs) were compared with an age and sex matched series of consecutive first-episode patients treated only with second-generation antipsychotics (SGAs). Rates of MetS were compared at baseline and after on average 3 years of treatment exposure.Results: At first episode there was no difference in the prevalence of MetS between the historic and the current cohort. Rates of MetS increased over time in both groups, but patients started on SGAs had a three times higher incidence rate of MetS (Odds Ratio 3.6, CI 1.7-7.5). The average increase in weight and body mass index was twice as high in patients started on SGA. The difference between the FGA and SGA group was no longer significant when patients started on clozapine and olanzapine were excluded. Conclusion:Rates of MetS at the first episode of schizophrenia today are not different from those of patients 15 to 20 years ago. This finding counters the notion that the high rates of metabolic abnormalities in patients with schizophrenia currently reported are mainly due to lifestyle changes over time in the general population. Some SGAs have a significantly more negative impact on the incidence of MetS compared to FGAs in first-episode patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review

Hert

Schreurs

Sweers

et al. 2008

Schizophrenia Research

219

118

View full text Add to dashboard Cite

show abstract

“…Metabolic syndrome has been used to describe a set of commonly co-occurring conditions that include obesity (particularly abdominal), insulin resistance, impaired glucose tolerance, disturbances in uric acid metabolism, hypertension, and prothrombotic and pro-inflammatory states, which can increase the risk of CVD [4]. Its incidence and prevalence have risen dramatically, especially in the western countries, as a result of the increasing prevalence of obesity [5].…”

Section: Introductionmentioning

confidence: 99%

Prevalence of Metabolic Syndrome amongst Bipolar Patients on Lithium and Sodium Valproate Monotherapy

Abba‐Aji¹

2017

J Psychiatry

View full text Add to dashboard Cite

“…Sedentary lifestyle, poor dietary awareness or unhealthy eating choices, lack of exercise, smoking and substance abuse are associated with high morbidity and mortality [2]. The landmark CATIE study and several others support a link between antipsychotic use and metabolic syndrome [3][4][5]. A number of studies indicate a substantial increase in prevalence of metabolic syndrome in women compared with men [6][7][8][9][10].…”

Section: Introductionmentioning

confidence: 99%

“…Based on the NCEP ATP III criteria the prevalence of metabolic syndrome varies between 8%-43% in men and from 7%-56% in women around the world [19]. The CLAMORS Study assessed patients for coronary heart disease (CHD) and metabolic syndrome and concluded that those on antipsychotics had prevalence in the same range as the general population 10-15 years older [5].…”

Section: Introductionmentioning

confidence: 99%

Lester Adaptation of Cardio Metabolic Measurements: An Inpatient Interventional Framework for Women with Mental Illness

M¹,

Lotfy²,

L³

2017

Endocrinol Metab Syndr

View full text Add to dashboard Cite

Aims of the study: To assess the prevalence of metabolic syndrome and implement a framework for screening and management of cardio metabolic risks in women on psychiatric in-patient wards.Background: An estimated 29-48% of psychiatric in-patients have metabolic syndrome. Severe mood disorders and psychotic illnesses are independent risk factors. 20-25% of the world's adult population have metabolic syndrome and they are twice as likely to die from and three times as likely to have a heart attack or stroke compared with people without the syndrome. This study gives an overview of the application of Lester Tool on busy in-patient units and interventional approaches adapted by the team.

show abstract

Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: Results of the CLAMORS Study

Cited by 172 publications

References 57 publications

Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review

Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review

Prevalence of Metabolic Syndrome amongst Bipolar Patients on Lithium and Sodium Valproate Monotherapy

Lester Adaptation of Cardio Metabolic Measurements: An Inpatient Interventional Framework for Women with Mental Illness

Contact Info

Product

Resources

About